Insights into the Role of PPARβ/δ in NAFLD.

Détails

Ressource 1Télécharger: ijms-19-01893.pdf (1829.74 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_607C77FFAC76
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Insights into the Role of PPARβ/δ in NAFLD.
Périodique
International journal of molecular sciences
Auteur(s)
Chen J., Montagner A., Tan N.S., Wahli W.
ISSN
1422-0067 (Electronic)
ISSN-L
1422-0067
Statut éditorial
Publié
Date de publication
27/06/2018
Peer-reviewed
Oui
Volume
19
Numéro
7
Pages
1893
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is a major health issue in developed countries. Although usually associated with obesity, NAFLD is also diagnosed in individuals with low body mass index (BMI) values, especially in Asia. NAFLD can progress from steatosis to non-alcoholic steatohepatitis (NASH), which is characterized by liver damage and inflammation, leading to cirrhosis and hepatocellular carcinoma (HCC). NAFLD development can be induced by lipid metabolism alterations; imbalances of pro- and anti-inflammatory molecules; and changes in various other factors, such as gut nutrient-derived signals and adipokines. Obesity-related metabolic disorders may be improved by activation of the nuclear receptor peroxisome proliferator-activated receptor (PPAR)β/δ, which is involved in metabolic processes and other functions. This review is focused on research findings related to PPARβ/δ-mediated regulation of hepatic lipid and glucose metabolism and NAFLD development. It also discusses the potential use of pharmacological PPARβ/δ activation for NAFLD treatment.
Mots-clé
Animals, Carcinoma, Hepatocellular/drug therapy, Carcinoma, Hepatocellular/metabolism, Humans, Liver Neoplasms/drug therapy, Liver Neoplasms/metabolism, Non-alcoholic Fatty Liver Disease/drug therapy, Non-alcoholic Fatty Liver Disease/metabolism, PPAR delta/metabolism, PPAR delta/therapeutic use, PPAR-beta/metabolism, PPAR-beta/therapeutic use, NAFLD, NASH, PPARβ/δ, lipid metabolism, liver, steatosis
Pubmed
Web of science
Open Access
Oui
Création de la notice
13/09/2018 8:34
Dernière modification de la notice
20/08/2019 15:17
Données d'usage